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• Offer trastuzumab, administered at three-week intervals for one year or until disease recurrence (whichever is the shorter period), as an adjuvant treatment to patients with HER2-positive early invasive breast cancer following surgery, chemotherapy, and radiotherapy when applicable.
• Assess cardiac function before starting treatment with trastuzumab. Do not offer trastuzumab treatment to patients who have any of the following:
• a left ventricular ejection fraction (LVEF) of 55% or less
• a history of documented congestive heart failure
• high-risk uncontrolled arrhythmias
• angina pectoris requiring medication
• clinically significant valvular disease
• evidence of transmural infarction on electrocardiograph (ECG)
• poorly controlled hypertension Patients receiving trastuzumab should be reviewed regularly and monitored for side effects by clinicians familiar with the drug.
• Adjuvant trastuzumab should be offered with chemotherapy following surgery in patients with node positive or node negative tumours larger than 1 cm. Trastuzumab concurrently with an anthracycline is not recommended due to risk of cardiotoxicity.
Trastuzumab can be offered to patients who require radiotherapy, although long-term toxicity is unknown. 
Supplementary
HER2+, operable, Stage I-III, N+ or high-risk N0 39% <2 cm 51% between 2.1−4.9 cm 8% ≥5 cm 13% N0
Initially only N+ disease; as of • Did not find association between MYC amplification and additional trastuzumab benefit 37
• Trastuzumab benefit seemed independent of HER2 centromere 17 ratio and chromosome 17 copy number 38
• Both HR+ and HR− pts benefit from trastuzumab (HR=0. Abbreviations: AC; doxorubicin + cyclophosphamide; DDFS, distant disease-free survival; DFS, disease-free survival; EC, epirubicin + cyclophosphamide; ER, estrogen receptor; FEC, fluorouracil + epirubicin + cyclophosphamide; HER2, human epidermal growth factor receptor 2; HR-, hormone receptor negative; HR+, hormone receptor positive; LVEF, left ventricular ejection fraction; LABC, locally-advanced breast cancer; N+, node-positive; N0, node-negative; OS, overall survival; pCR, pathologically complete response; RT, radiation therapy; TCH, docetaxel + carboplatin + trastuzumab; T, docetaxel; T-DM1, trastuzumab emtansine; TH, docetaxel + trastuzumab.
